Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative

Research and development

Amortization of acquired intangibles

Restructuring - operating expenses

Acquisition related expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

ResMed

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

ResMed reports robust Q1 performance, eyes margin expansion and partnerships

ResMed's Q1 2023 performance reflects strong revenue growth and a focus on meeting global demand for connected CPAP and APAP devices. The company faces challenges in maintaining gross margins and managing operating expenses but sees opportunities in expanding margins and engaging with new patient segments.

ResMed reports robust Q2 earnings, eyes growth through innovation

ResMed's Q2 2023 earnings call highlighted strong sales growth, increased revenue, and a focus on innovation.
Challenges in supply chain constraints and operating expenses were noted, alongside opportunities in growth drivers.
The company aims to improve lives through respiratory care solutions and digital health innovations by 2025.
ResMed's performance reflects post-COVID awareness of respiratory health importance and customer acceptance of new devices.

ResMed reports robust Q3 performance, eyes global growth opportunities

ResMed's Q3 earnings call highlighted strong financial performance, growth in device revenue and mask sales, and a focus on sustaining profitable growth. The company aims to address challenges in gross margin decline by leveraging opportunities for expansion and reinvestment in growth.

ResMed reports strong Q4 earnings, eyes international growth opportunities

ResMed's Q4 2023 showcased robust financial performance with revenue and earnings growth.
The company's focus on patient care, innovation, and international expansion presents promising opportunities.
Challenges include managing operating expenses, gross margin decline, and pricing dynamics.
Strategic initiatives to improve gross margins and drive revenue growth position ResMed well for the future.

ResMed reports 16% revenue growth in Q1 2024 earnings call

ResMed's Q1 2024 performance showcased revenue growth driven by strong device and mask sales globally.
Despite challenges like margin decline and increased expenses, the company's strategic focus on core business and innovation remains strong.
Opportunities lie in expanding alternative therapies, sustaining growth in devices and masks, and optimizing the SaaS business.
Overall, ResMed is positioned for accelerated profitable growth, prioritizing cost optimization and key initiatives for future success.

ResMed reports strong Q2 earnings, eyes global healthcare expansion

ResMed's Q2 2024 earnings call showcased robust financial performance, strategic priorities in healthcare innovation, and a focus on delivering value through patient care. Despite challenges, the company remains optimistic about growth potential and stakeholder engagement in its mission.

ResMed reports strong Q3 results, eyes global expansion and innovation

ResMed's Q3 earnings call showcased solid financial performance, operational improvements, and a strategic focus on market expansion. With a strong emphasis on innovation and cost discipline, the company is poised for continued growth despite challenges.

ResMed reports robust Q4 growth, eyes digital health opportunities

ResMed's Q4 performance was strong, driven by robust growth and financial stability.
While facing challenges like medication impact and market expansion, opportunities in digital health and partnerships exist.
The company's focus on patient awareness and demand generation remains key to future growth.
Overall, ResMed's strategic initiatives position it well for continued success and innovation.

ResMed excels in Q1 with strong revenue growth and innovation

ResMed's Q1 performance reflects strong revenue growth, product success, and strategic investments.
The company's strengths lie in innovation, supply chain optimization, and proactive growth strategies.
Challenges include competitive pressures, addressing new patient demand, and balancing acquisitions with operational efficiency.
Opportunities abound in digital health, customer partnerships, and expanding patient care pathways.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ResMed (RMD) is optimistic about maintaining growth momentum on several recent developments.

ResMed (RMD) Stock Hits New 52-Week High: What's Driving It?

ResMed Inc. (RMD) CEO Mick Farrell on Q2 2020 Results - Earnings Call Transcript

This medical device maker reported solid top line growth while edging out Wall Street's expectations.

ResMed Reports Fiscal Q2 Results, Earnings Up 29%

ResMed (RMD) delivered earnings and revenue surprises of 19.80% and 1.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) Q2 Earnings and Revenues Top Estimates

Boston Scientific

Royal Philips

Growth in the COPD devices market can be attributed to factors like steadily rising geriatric population, increasing incidence of smoking and chronic respiratory diseases.

COPD Devices Gain Regulatory Go-Ahead: 3 Stocks in Focus

ResMed (RMD) launches its first tube-up, full-face CPAP mask, thus completing its full-face mask portfolio.

ResMed Launches AirFit F30i CPAP Mask, Widens Client Base

Five whistleblower lawsuits allege the company was illegally paying healthcare providers to use its devices.

ResMed Will Pay $37 Million to Settle Kickback Dispute With DOJ

NuVasive

NUVA vs. RMD: Which Stock Is the Better Value Option?

CONMED

DexCom

Tandem Diabetes Care

West Pharmaceutical Services

Banking on the three key trends, we zero in on six MedTech stocks that are likely to deliver stellar performance in 2020.

6 MedTech Stocks That are Set to Beat the Market in 2020

ResMed (RMD) gains from impressive performance of its SaaS business.

ResMed (RMD) Hits a 52-Week High: What's Driving the Stock?

Does ResMed (RMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why ResMed (RMD) is a Great Choice

ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think " Yes "

Prologis

Boston Beer Company

Spark Energy

Vertex Pharmaceuticals

On Dec 9, the fear gauge jumped 16% as uncertainties in the closure of U.S.-China trade deal instilled fear in investors.

5 Defensive Stocks to Buy as Volatility Index Soars

Booz Allen Hamilton Hld

McGrath RentCorp

SS&C Technologies Hlds

United Technologies

Although the dividend growth stocks do not necessarily have the highest yields, they have outperformed for a longer period than the broader stock market or any other dividend-paying stock.

5 Dividend Stocks That Possess Strong Growth Potential

Microsoft

Ruth's Hospitality Group

Zoetis

If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

4 GARP Stocks to Scoop Up for Maximum Returns.

Investors continue to be optimistic about ResMed (RMD) on its stellar performance.

Here's Why You Should Invest in ResMed (RMD) Stock Right Now

Align Technology

Edwards Lifesciences

Globus Medical

LeMaitre Vascular

QuidelOrtho Corp

Repligen

Medical technology companies are rising bullishly in 2019. The best-performing medical stocks tend to have high Composite Ratings, reflecting strong growth metrics vs.

These Medical Stocks Are Outperforming 95% Of All Stocks — Here's Why

NUVA or RMD: Which Is the Better Value Stock Right Now?

Lam Research

Northrop Grumman

Nexstar Media Group

Qorvo

Sales growth is a key measure for a company, as it helps investors understand the sustainability of its earnings growth.

5 Best Stocks With Strong Sales Growth to Buy Right Away

S&P Global

Target

Investors can earn both a good dividend and some capital appreciation with these stocks.

Soaring More Than 30%, These 3 Dividend Stocks Are Not Too Good to Be True

Apple

Amazon

Cracker Barrel Old Country Store

Five Below

Kraft Heinz

Sherwin-Williams

Ulta Beauty

These nine companies should fatten investors’ portfolios over the next decade because they're the best stocks to buy and hold.

The 9 Best Stocks to Buy for the Next Decade

Social Capital Hedosophia Hlds

Tesla

Markets finished the week on a positive note.

Why Tesla, Social Capital Hedosophia Holdings, and ResMed Jumped Today

Shares hit an all-time high after the medical device maker posts strong quarterly results.

Why ResMed Stock Is Shooting Higher Today

ResMed (RMD) registers growth at CER across its key operating segments in Q1.

ResMed's (RMD) Q1 Earnings Beat Estimates, Margins Expand

The healthcare company easily topped Wall Street revenue and earnings estimates.

News for ResMed Stock (RMD)